Join to access to all OVN content. Join for Free

Results for 'Hematology Oncology'

Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program
OVN Avatar Cheryl Ho, MD, Howard J. Lim, MD, Dean A. Regier, PhD
Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program

canada, oncology, malignant, hematology, HTC

Canadian regulatory approvals align with FDA decisions, but submission numbers to Health Canada (HC) and Health Technology Assessment (HTA) processes are lower in Canada. There is a nearly 3-year delay between Accelerated Approval (AA) and funded access to treatment for Canadians. HTA in Canada …

Jun 5th • 6 mins read

Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016
OVN Avatar Jiaxi Zhou, Jonathon Vallejo, Paul Kluetz, Richard Pazdur, Tamy Kim, Patricia Keegan, Ann Farrell, Julia A Beaver, Rajeshwari Sridhara
Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016

drug approval, medical oncology, united states food and drug administration, hematology, surrogate endpoints, marketing, accelerated approval

Background: An overview was conducted of oncology products reviewed by the Office of Oncology Drug Products (OODP) at the FDA for marketing approval between July 2005 and December 2007. The study aims to understand the impact of post-2007 changes in laws, regulations, and organizational structure …

Aug 4th • 15 mins read

The FDA Oncology Center of Excellence and Precision Medicine
OVN Avatar Kirsten B Goldberg, Gideon M Blumenthal, Amy E McKee and Richard Pazdur
The FDA Oncology Center of Excellence and Precision Medicine

Biomarkers, drugs, hematology, medicine, oncology, precision medicine, regulation

The FDA is exploring real-world evidence to enhance understanding of the long-term safety and efficacy of oncology drugs. Initiatives like the Information Exchange and Data Transformation initiative are building infrastructure for big-data analytics. Additionally, patient-focused programs aim to inc…

Nov 6th • 3 mins read

First person profile: Supriya G. Mohile, MD, MS: A respected geriatric oncologist, Dr. Mohile has conducted innovative research on improving care for older patients with cancer
OVN Avatar Carrie Printz
First person profile: Supriya G. Mohile, MD, MS: A respected geriatric oncologist, Dr. Mohile has conducted innovative research on improving care for older patients with cancer

Supriya G. Mohile, geriatric oncologist

  Ms. Canin and Dr. Mohile collaborated to involve patients and caregivers in geriatric oncology studies, forming the SCOREboard advisory group. Dr. Mohile received a $2 million grant to create infrastructure for cancer and aging studies, and she is recognized as a leader in geria…

Oct 11th • 2 mins read

Related Topics

Loading...